Clinical Trial AdvancementsThe combination therapy of CTX-009 and CTX-471 demonstrates significant potential in eliminating MHC-1 negative tumors, offering a new hope for patients with these resistant cancers.
Financial HealthWith a solid cash position, the company is well-financed to support ongoing operations and clinical trials into mid-2026, ensuring continued progress in its innovative pipeline.
Regulatory MilestonesFDA clearance for CTX-8371 marks a major regulatory milestone, paving the way for further clinical development and potentially enhancing treatment options for patients.